The development of effective cancer vaccines remains an urgent, but as yet unmet, clinical need. This deficiency is in part due to an incomplete understanding of how to best invoke dendritic cells (DC) that are crucial for the induction of tumor-specific CD8 + T cells capable of mediating durable protective immunity. In this regard, elevated expression of the transcription factor X box-binding protein 1 (XBP1) in DC appears to play a decisive role in promoting the ability of DC to cross-present Ags to CD8 + T cells in the therapeutic setting. Delivery of DNA vaccines encoding XBP1 and tumor Ag to skin DC resulted in increased IFN-a production by plasmacytoid DC (pDC) from skin/tumor draining lymph nodes and the cross-priming of Ag-specific CD8 + T cell responses associated with therapeutic benefit. Antitumor protection was dependent on cross-presenting Batf3 + DC, pDC, and CD8 + T cells. CD103 + DC from the skin/tumor draining lymph nodes of the immunized mice appeared responsible for activation of Ag-specific naive CD8 + T cells, but were dependent on pDC for optimal effectiveness. Similarly, human XBP1 improved the capacity of human blood-and skin-derived DC to activate human T cells. These data support an important intrinsic role for XBP1 in DC for effective cross-priming and orchestration of Batf3 + DC-pDC interactions, thereby enabling effective vaccine induction of protective antitumor immunity. The Journal of Immunology, 2015, 194: 000-000. I mmunotherapies utilizing vaccines, Abs, and T cells have the potential to (re)activate and optimize the body's immune system to fight off cancer (1) . Although vaccines are capable of eliciting robust, durable, and protective tumor Ag-specific CD8 + T effectors to limit tumor progression or disease recurrence, such approaches have typically resulted in only modest clinical efficacy to date (1, 2) . The limited efficacy may relate to the inability of current vaccine formulations to optimally invoke dendritic cell (DC) subpopulations in vivo, leading to inefficient induction (via DC-mediated cross-priming) and maintenance of tumor Ag-specific CD8 + T cell responses (2-4). Although drugs (e.g., chloroquine) that block endosomal and phagosomal acidification and the targeting of DC-specific receptors (e.g., DEC205, DNGR-1) for directed Ag uptake can improve the efficiency of DC-mediated cross-presentation, it has proven difficult to translate such findings into effective cancer vaccine formulations (4) . An alternate strategy would be to (epigenetically) accentuate the ability of DC to mediate productive Ag-specific cross-priming via the use of DNA-based vaccines that represent an off-the-shelf, easily scalable treatment platform (5-7). Although several DNA vaccines have been licensed for veterinary use, current DNA vaccines have displayed only limited efficacy in humans (7) , which may relate to their low efficiency in transfecting rare-event DC within vaccine sites in vivo. Furthermore, among all DC subsets, cross-presenting DC subpopulations (e.g., Batf3-dependent CD8a + and CD103 + DC [Batf3 + DC]) are preferred targets for cancer vaccine Ag uptake in both humans and mice (8) (9) (10) (11) . Additionally, optimal DC-mediated cross-priming of CD8 + T cells requires type 1 IFN (12) (13) (14) . Hence, an ideal vaccine would optimize the collaborative interaction of cross-presenting DC and type 1 IFN-producing plasmacytoid DC (pDC) to elicit and sustain robust tumor-specific CD8 + T cell-mediated protective immunity.
The transcription factor X box-binding protein 1 (XBP1) appears unique in its intrinsic ability to promote the differentiation, survival, and function of DC subsets, including pDC and CD8a + DC (15, 16) . XBP1 synergizes with TLR agonists to increase type 1 IFN production and other inflammatory cytokines from various cells such as DC (17) (18) (19) (20) , and it plays a critical role in the ability of humans to respond to vaccination against the influenza virus (21). Our data indicate that ectopic delivery of XBP1 cDNA in a DNA-based vaccine formulation improves the ability of endogenous Batf3 + DC and pDC to collaboratively orchestrate the cross-priming of therapeutic antitumor CD8 + T cells in multiple clinically relevant murine tumor models. These results support the prospective development of similar genetic vaccine approaches for the treatment of patients with cancer.
Materials and Methods
Mice and cell lines C57BL/6 (B6)-wild-type (WT), -Batf3 2/2 , -TLR3 2/2 , and -Rag2/OT-I mice and BALB/c-WT and -Batf3 2/2 mice (females, 6-8 wk of age) were purchased from The Jackson Laboratory (Bar Harbor, ME) or Taconic Biosciences (Rensselaer, NY). B6/129S-Batf3 2/2 mice were obtained through B6 mice backcrossed with 129S-Batf3 2/2 mice (8) for five generations. The inducible Braf V600E /Pten-driven melanoma model (22) was provided by Dr. M. Bosenberg (Yale University). All mice were housed and bred in specific pathogen-free conditions in the University of Pittsburgh Animal Facility. All animal procedures were performed according to Institutional Animal Care and Use Committee-approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. Murine melanoma B16 (American Type Culture Collection, Manassas, VA) and glioma GL26 cells were maintained in DMEM (Irvine Scientific, Santa Ana, CA) supplemented with 10% FBS (HyClone, Logan, UT), 2 mmol/l glutamine (Invitrogen, Carlsbad, CA), and 13 antibiotic/ antimycotic solution (Sigma-Aldrich, St. Louis, MO), and murine breast carcinoma 4T1.2-Neu cells were cultured in the aforementioned medium including G-418 (500 mg/ml) (Invitrogen) (23, 24) .
Plasmids
DNA encoding murine self/tumor Ag tyrosinase-related protein 2 (TRP2), rat oncoantigen Neu extracellular domain (NeuED), or human MAGEA3 was fused to human heat shock protein 70 (hsp70) (TRP2hsp70, NeuEDhsp70, or MAGEA3hsp70) and was described previously (25) (26) (27) . DNA encoding XBP1 driven by DC-specific CD11c promoter and TRP2hsp70 as well as NeuEDhsp70 driven by constitutive mammalian CMV promoter (XBP1/TRP2hsp70 or XBP1/NeuEDhsp70) were recently reported (23) . DNA encoding human XBP1 and dominant-negative mouse XBP1 (dnXBP1) (15) were provided by Dr. L. Glimcher (Weill Cornell Medical College). Human XBP1 short hairpin RNA (shRNA; sc-38627-SH) and control shRNA DNA were purchased from Santa Cruz Biotechnology (Paso Robles, CA). All DNA was prepared using an endotoxin-free DNA purification kit (Qiagen).
DC generation and transfection
For murine bone marrow-derived DC, bone marrow cells (2-3 3 10 6 /ml) from naive BALB/c or B6 mice (females, 6-8 wk) were cultured in DC culture medium (RPMI 1640 [Irvine Scientific] supplemented with 10% FBS, 2 mmol/l glutamine, 13 antibiotic/antimycotic solution, recombinant mouse GM-CSF [1000 U/ml], and IL-4 [1000 U/ml] [PeproTech]) (23) . On days 5-6, DC were purified using anti-mouse CD11c microbeads (Miltenyi Biotec, Auburn, CA). Purified DC (2-3 3 10 6 ) were untreated or transfected with 7 mg endotoxin-free DNA using an Amaxa mouse DC Nucleofector kit (Lonza, Cologne, Germany), following the vendor's instructions, and continually cultured in 1 ml DC culture medium for 2-3 d before analysis or immunization (24) .
For human monocyte-derived DC (moDC), immature human moDC were generated from PBMC obtained from adult healthy donors with written consent under an Institutional Review Board-approved protocol in DC culture medium (AIM V medium [Invitrogen] supplemented with recombinant human IL-4 [20 ng/ml; PeproTech], and clinical-grade recombinant human GM-CSF [Leukine, 1000 U/ml; Bayer]) (24) . On days 5-6, moDC (3 3 10 6 ) were untreated or transfected with 7 mg endotoxin-free DNA using an Amaxa human DC Nucleofector kit (Lonza), following the vendor's instruction, and continually cultured in 1 ml DC culture medium for 2 d before use.
For human skin-derived DC, human skin from surgical discard was obtained under an Institutional Review Board-approved protocol. Human skin epidermal/dermal explants were prepared from abdominal skins with a skin graft knife and subsequently untreated or immunized by 0.6-mm gold particles (Bio-Rad Laboratories) conjugated with DNA using a gene gun (GG) under sterile conditions (24) . After vaccination, skins were cultured on a sterile steel mesh with the epidermal side up in AIM V medium supplemented with 13 antibiotic/antimycotic solution at 37˚C in 5% CO 2 . Three days later, skin migratory DC were harvested from the culture medium and were stained with anti-HLA-DR-Alexa Fluor 488, -CD14-Brilliant Violet 570, -CD11c-PerCP-Cy5.5, and -CD141-allophycocyanin or isotype control Abs (BD Biosciences, eBioscience, BioLegend) and then analyzed by flow cytometry using a BD LSR II (BD Biosciences). CD14 + DC were isolated from harvested skin DC using the EasySep human CD14 + selection kit (StemCell Technologies) per the vendor's instruction.
Western blotting
Untreated and DNA-transfected DC were harvested, washed, and lysed using CelLytic M cell lysis reagent (Sigma-Aldrich). Sec22b protein from equivalent numbers of DC (1.25 3 10 5 ) was collected and analyzed by standard Western blot using mouse anti-Sec22b Ab (29-F7, Santa Cruz Biotechnology) as a probe. Mouse b-actin or GADPH detected by antimouse b-actin or GADPH Ab (Sigma-Aldrich) served as internal-loading controls. Immunoreactive protein bands were visualized using appropriate HRP-linked secondary Ab and SuperSignal West Femto maximum sensitivity substrate (Pierce, Rockford, IL) as described previously (23) .
Analyses of DC subsets in skin/tumor draining lymph nodes For skin/tumor draining lymph nodes (dLN) CD8a + DC and CD103 + DC function, B6 mice (females, 6-8 wk, 10/group) were injected s.c. in the left flank with GL26 (1 3 10 6 ) tumor cells on day 0. On day 8, tumor-bearing mice were left untreated or they were vaccinated using a GG with XBP1/ TRP2hsp70 DNA as previously described (23 For IFN-a production by pDC from skin/tumor dLN, BALB/c mice (females, 6-8 wk, five per group) were s.c. injected with 4T1.2-Neu (2 3 10 4 ) tumor cells on day 0. Eight days later, tumor-bearing mice were left untreated or they were vaccinated using a GG with XBP1 or Aghsp70 (NeuEDhsp70 or TRP2hsp70 as GG-mediated vaccination controls) DNA. After 3 d, pDC were isolated from pooled skin/tumor dLN using a mouse pDC isolation kit (Miltenyi Biotec). Isolated pDC (2 3 10 4 ) were cultured in 200 ml RPMI 1640 supplemented with 10% (v/v) FBS for 24 h without stimulation. IFN-a in the culture supernatants was measured by ELISA (eBioscience). 
Ag cross-presentation

T cell activation
For naive mouse T cell activation, untreated or XBP1/TRP2hsp70 or control DNA-transfected DC (6 3 10 4 ) were cocultured with syngeneic CD8 + T cells (3 3 10 5 ) isolated from splenocytes of naive B6 mice using antimouse CD8 microbeads (Miltenyi Biotec) in 200 ml RPMI 1640 containing 10% (v/v) FBS for 3 d. On day 6 of DC/T cell coculture, T cells were then restimulated with MAGEA3hsp70-transfected autogolous moDC (2 3 10 4 ) for 6 d. ) (22) . Braf V600E /Pten-driven melanoma (∼3 mm)-bearing mice (two to three per group) were left untreated or they were vaccinated using a GG with XBP1/ TRP2hsp70 DNA on days 0, 7, and 14 as described previously (23) . On day 60, CD8 + T cells were purified from splenocytes and skin/tumor dLN using anti-mouse CD8 microbeads. Purified CD8 + T cells (2 3 10 5 ) were cocultured with syngeneic DC (4 3 10 4 ) transfected with TRP2hsp70 DNA or pulsed by Braf V600E /Pten-driven melanoma lysates (irrelevant NeuEDhsp70 DNA-transfected and 4T1.2-Neu lysate-pulsed DC as Ag-or tumor-specific controls) in 200 ml RPMI 1640 supplemented with 10% (v/v) FBS for 3 d. IFN-g in the culture supernatants was determined by ELISA.
Vaccine models using transplantable tumors
For DC vaccination, BALB/c or B6 mice (females, 6-8 wk, three per group) were inoculated s.c. with exponentially growing 4T1.2-Neu (2 3 10 4 ) in the fourth mammary fat pad or with GL26 (1 3 10 6 ) in the right flank on day 0 (24). On day 8, tumor-bearing mice were randomized into cohorts and left untreated or treated by i.p. immunization with DC (2.5 3 10 5 ) in 100 ml endotoxin-free 13 PBS (Sigma-Aldrich).
For DNA vaccination, B6-WT, -Batf3 2/2 , and -TLR3 2/2 mice or B6/ 129S-Batf3 2/2 mice (females, 6-8 wk, three to five per group) were left untreated or they were vaccinated using a GG with XBP1/TRP2hsp70 DNA on days 1, 7, and 14. On day 21, mice were inoculated s.c. with exponentially growing B16 melanoma cells (5 3 10
mice (females, 6-8 wk, five per group) were inoculated s.c. with GL26 (1 3 10 6 ) on day 0. GL26-bearing mice were the randomized into cohorts and left untreated or they were vaccinated using a GG with XBP1/ TRP2hsp70 DNA on days 9 and 14. BALB/c-WT or -Batf3 2/2 mice (females, 6-8 wk, three to five per group) were inoculated s.c. with 4T1.2-Neu (2 3 10 4 ) on day 0. When primary 4T1.2-Neu reached ∼3 mm, tumorbearing mice were randomized and left untreated or they were vaccinated using a GG with XBP1/NeuEDhsp70 or control DNA one to three times (as indicated in the figure legends). In some experiments, pDC were depleted by i.p. injection of 200 mg anti-mouse pDC Ab (120G8; Bio X Cell, West Lebanon, NH) 1 d before, on the day of, and 1 d after vaccination.
Treatment of genetically engineered Braf
V600E /Pten-driven melanoma mouse model of human disease 4-HT induced melanomas in B6-Tyr-Cre
ERT2
Braf
CA Pten lox/lox mice (22) were allowed to progress to a mean tumor size of ∼3 mm, at which time the melanoma-bearing mice were randomized into cohorts of three to four mice exhibiting a comparable mean tumor size. Mice were then left untreated or they were vaccinated using a GG with XBP1/TRP2hsp70 DNA on days 0, 7, and 14. To deplete CD8 T cells, anti-mouse CD8 mAb (53-6.7) (200 mg/injection) was injected i.p. 1 d before, on the day of, and the 1 and 3 d after first vaccination and then once a week thereafter. Specific T cell depletion (.95%) was verified by flow cytometry monitoring of PBLs isolated by tail venipuncture.
Tumor and animal survival monitoring
Primary tumor area was determined every 3 d as the product of orthogonal measurements determined using digital slide calipers (Fisher Scientific, Pittsburgh, PA). Mice were euthanized when tumor .10 mm in mean diameter. On day 30 after 4T1.2-Neu inoculation, mice were euthanized and harvested lungs were fixed with Bouin's solution (Sigma-Aldrich) for enumeration of 4T1.2-Neu metastatic foci. Bone marrow was also isolated from these animals for quantitation of site-specific metastases (26) .
Statistical analysis
Data were analyzed for statistical significance using a Student t test (immune assays, tumor size, and foci) (GraphPad Prism version 6) or the log rank test (GraphPad Prism version 6) as indicated in the text. Animal survival is reported in Kaplan-Meier survival (i.e., time to euthanasia) curves. A p value ,0.05 is considered to be statistically significant.
Results
XBP1 potentiates the therapeutic antitumor efficacy of ex vivo-generated DC vaccines
Vaccines implementing ex vivo-generated autologous/syngeneic DC have been extensively evaluated, but they have thus far resulted in only modest clinical efficacy in the cancer setting (1, 2) . Similarly, we observed that even DC genetically engineered to express tumor Ag (e.g., NeuED or TRP2) fused to hsp70 (to activate and promote enhanced cross-priming of T cells by DC; see Ref. 29 ) did not elicit therapeutic immunity against clinically relevant 4T1.2-Neu breast carcinomas or GL26 (which intrinsically expresses TRP2) in vivo (Fig. 1A-C , Table I ). To improve the immunostimulatory capacity of DC-based vaccines, we have recently developed DC genetically modified to overexpress the transcriptional activator XBP1 in addition to Aghsp70 (XBP1/Aghsp70 DC) and showed that these DC display enhanced survival and an augmented T cell stimulatory phenotype (e.g., increased expression/production of CD86, IL-15Ra, IL-6, TNF-a; see Ref. 23) . We now show that XBP1/Aghsp70 DC readily activates Ag-specific naive CD8 + T cells in vitro (Supplemental Fig. 1A, 1B) , and, more importantly, when applied as a single immunization, small numbers (2.5 3 10 5 ) of these cells rapidly and efficiently elicit durable therapeutic immunity against established 4T1.2-Neu breast carcinomas or GL26 gliomas (Fig. 1A-C) . Using a dominant-negative form of XBP1 (dnXBP1), which inhibits XBP1 activity but does not affect cell viability and growth (15), we further showed that antagonism of XBP1 function in XBP1/Aghsp70 DC abrogates their therapeutic efficacy in vivo (Fig. 1D) .
XBP1-based ex vivo-generated DC and in vivo DC-targeting DNA vaccines elicit therapeutic antitumor immunity against spontaneous lung and bone marrow metastases Activated oncoantigen rat Neu-expressing 4T1.2-Neu tumor cells efficiently spread to distant organ sites (e.g., bone marrow, lung) after initial implantation in the mammary fat pad (26) . To determine the therapeutic antitumor benefit of DC engineered to overexpress XBP1 in vitro or in vivo (23), we employed treatment regimens to 4T1.2-Neu-bearing female mice, including 1) ex vivo-generated DC were coordinately transduced to express XBP1 and Aghsp70 prior to administration as a vaccine, and 2) DNA encoding XBP1 driven off a CD11c-promoter (XBP1 DCtargeting; see Ref. 23 ) and Aghsp70 were delivered into the skin using a biolistic GG where in situ expression would be restricted to dermal DC. In both cases, we observed vaccine-associated therapeutic benefit against both primary 4T1.2-Neu tumors ( Fig. 1) mice are deficient in cross-presenting CD8a + DC and CD103 + DC, which are required for the spontaneous priming of tumor-specific CD8 + T cell responses in vivo, but these mice otherwise exhibit normal T cell and (alternate) DC subset phenotypes (8, 12, 13) . We noted that antitumor immunity elicited by skin immunization with XBP1 DC-targeting DNA vaccines was abrogated in Batf3 2/2 mice in the B16 melanoma, 4T1.2-Neu breast carcinoma, and GL26 glioma model systems (Fig. 3A-D) . Furthermore, we determined that TLR3 (expressed at high levels on CD8a + DC and CD103 + DC subsets; see Ref. 30, 31) was also critical to the antitumor efficacy of this vaccination approach because this treatment regimen was ineffective in tumor-bearing TLR3 2/2 recipient mice (Supplemental Fig. 2A ).
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Effective therapeutic skin immunization with XBP1 DC-targeting DNA vaccines requires IFN-a-producing pDC pDC are the major source for type I IFN, which is required for the effective cross-priming of CD8 + T cells (12) (13) (14) , and the prevalence of these APC was noted in 4T1.2-Neu and GL26 tumors growing progressively s.c. (Supplemental Fig. 3) . We observed that cutaneous delivery of XBP1 DC-targeting DNA vaccines promoted IFN-a production by pDC isolated from skin/tumor dLN (Fig. 3E) , and that depletion of pDC in tumor-bearing mice before, during, and after vaccination led to reduced therapeutic efficacy (Fig. 3F) . Notably, the presence of XBP1 cDNA was required in the DNA vaccination, because IFN-a was not produced at elevated levels by pDC isolated from tumor-bearing mice vaccinated with Aghsp70 (NeuEDhsp70 or TRP2hsp70) DNA vaccines (Fig. 3E ) that were poorly protective (23).
XBP1 DC-targeting TRP2hsp70 DNA vaccines promote robust type 1 melanoma (TRP2)-specific CD8 + T cell responses that are therapeutic in Braf V600E /Pten-driven melanoma models
The genetically engineered Braf V600E /Pten-driven melanoma model faithfully recapitulates human disease (22) and provides a model that may reliably predict the comparative clinical efficacy of interventional strategies designed for patients with melanoma. Cutaneous immunization with XBP1 DC-targeting TRP2hsp70 DNA vaccines resulted in the development of durable melanoma (TRP2)-specific CD8 + T cell responses in association with suppressed tumor growth (Fig. 4) . Ab depletion of CD8 + T cells in vivo abrogated the Tumor-bearing BALB/c mice were untreated or vaccinated by DNA (Fig. 2A) . On day 30, tumor cells in bone marrow were selected, and data from two independent experiments are shown and were statistically analyzed (26) . XBP1/NeuEDhsp70 versus untreated, NeuEDhsp70, or XBP1: p , 0.05.
vaccine-associated treatment benefits, supporting the critical antitumor activity of these effector cells (Fig. 4B) .
XBP1 enhances the intrinsic Ag cross-presentation capacity of DC
Engineered XBP1 overexpression in DC enhanced Sec22b expression (Fig. 5A, Supplemental Fig. 1C ), which plays a key role in Ag cross-presentation mediated by DC (32) . In particular, we observed that elevated XBP1 in DC improved cross-priming of Ag-specific naive CD8 + T cells in the well-defined OVA and OT-I (OVA-specific CD8 + T cells) systems (Fig. 5B, Supplemental Fig.  1D ). In the clinically relevant more physiological poorly immunogenic self/tumor Ag TRP2 and TRP2-specific CD8 + T cells from the TCR Tg mice setting, XBP1 improved the ability of TRP2hsp70 DC in cross-priming of TRP2-specific naive CD8 + T cells (Fig. 5C ). Antagonism of XBP1 activity (by inclusion of dnXBP1 DNA constructs) prevented Sec22b upregulation in DC and mitigated the cross-priming of Ag-specific naive CD8 + T cells (Fig. 5A-C) .
CD103
+ DC isolated from tumor-bearing mice immunized with XBP1 DC-targeting TRP2hsp70 DNA vaccines are competent to cross-prime TRP2-specific naive CD8 + T cells in a pDC-dependent manner
Skin migratory CD103
+ DC (not lymph node-resident CD8a + DC) isolated from the skin/tumor dLN of GL26-bearing mice treated with XBP1/TRP2hsp70 DNA vaccines effectively activated self/tumor Ag TRP2-specific naive CD8 + T cells from TCR Tg mice (Fig. 5D) . However, Ab depletion of pDC in tumor-bearing mice prior to cutaneous DNA immunization diminished the capacity of resident CD103 + DC to activate TRP2-specific naive CD8 + T cells (Fig. 5D ).
Human XBP1 enhances the immunogenicity of human blood-and skin-derived DC Human blood-derived moDC engineered by human XBP1 secreted elevated levels of proinflammatory cytokines (IL-6 and TNF-a; Supplemental Fig. 4A ) and strongly enhanced the ability of DC cotransduced with MAGEA3hsp70 cDNA to activate autologous T cells, which was abrogated by inclusion of XBP1 shRNA (Fig.  6A, 6B ). DC emigrating from human skin explants genetically immunized with human XBP1 and MAGEA3hsp70 cDNA augmented activation of human T cells when compared with comparable DC emigrating from explants vaccinated with XBP1 or MAGEA3hsp70 cDNA alone (Fig. 6C) . Interestingly, CD14
2 DC (but not CD14 + DC) were uniquely capable of activating human T cells in vitro (Fig. 6D) . These results support the notion that ectopic XBP1 gene engineering of human (blood/skin) DC may be expected to similarly improve their ability to promote superior antitumor T cell responses as a consequence of active, specific immunization in patients with cancer.
Discussion
Despite the recent successes reported for immunotherapies integrating adoptive T cell transfer or the administration of immune checkpoint inhibitors in cancer patients, rates for durable clinical benefit remain modest. Means by which to improve the frequency of durable responses likely include the development of novel combination immunotherapies, including vaccine approaches. To date, however, single modality vaccine strategies, including those based on patient DC, have proven disappointing in their antitumor efficacy. Such impotence may, at least in part, relate to the inefficient delivery of vaccine Ag to (and appropriate activation of) resident DC populations within sites of tissue vaccination responsible for the optimal cross-priming of protective (type 1) CD8 + T cell responses in vivo (2-4).
DC taking up, processing, and presenting exogenous Ag (i.e., cross-presenting) must be activated (e.g., increased costimulatory molecules and proinflammatory cytokines) to favor cross-priming (2-4). Conventional ex vivo-generated DC have been most commonly employed in human cancer vaccine trials; however, these cells are not specialized for efficient cross-presentation of (vaccine) Ag to autologous CD8 + T cells. Hence, the use of professional cross-priming DC or the ability to engineer conventional DC to FIGURE 2. XBP1-potentiated in vitrogenerated DC and in vivo DC-targeting DNA vaccines elicit therapeutic antitumor immunity against spontaneous lung metastases. 4T1.2-Neu-bearing mice (mammary fat pad) were left untreated or they were cutaneously vaccinated with XBP1/NeuEDhsp70 DNA on days 8, 15, and 22, or i.p. with XBP1/NeuEDhsp70 cDNA-engineered syngeneic DC 8 d after tumor cell inoculation. On day 30 after tumor inoculation, mice were sacrificed and lungs were fixed with Bouin's solution for enumeration of 4T1.2-Neu metastatic foci. Data from three (A) or two (B) independent experiments are depicted and statistically analyzed as described in Materials and Methods. *p , 0.05, ***p , 0.001. reproducibly acquire cross-priming capacity would be envisioned to yield superior cell-based vaccine strategies in the cancer setting. XBP1 as a transcription factor controls expressions of many cell type-or condition-specific target genes (17, 19) . To establish the influence of XBP1 on both mouse and human DC, DC were not intentionally activated with DC maturation factors (e.g., LPS, cytokines) (Figs. 1, 2 , 5, 6) (23). "Poor" (suboptimal) control DC (i.e., untreated or XBP1 DC without Ag, Aghsp70 DC without XBP1) did not effectively activate T cells and elicit antitumor immunity (Figs. 1, 2 , 5, 6) (23). These data indirectly support the finding that XBP1 may improve DC functions (e.g., cross-presentation, antitumor effect). In this regard, we think that XBP1 plays a decisive intrinsic role in DC-mediated cross-priming, with even a single i.p.
immunization with small numbers of cultured XBP1/Aghsp70 cDNA-engineered DC proving sufficient to elicit durable therapeutic antitumor immunity in our several clinically relevant murine tumor models. XBP1 as an unfolded protein response-associated factor regulates endoplasmic reticulum structure and function and promotes the production and secretion of proteins (e.g., vaccine Ag) and DC survival (15, 17) . Whether the observed XBP1-enhanced effects (e.g., Ag cross-presentation) are due to impact of XBP1 on DC survival and effects on unfolded protein response will be investigated in the future to further define the underlying mechanisms.
XBP1 alone might not provide a signal that activates DC, and Aghsp70 might function synergistically with XBP1-initiated sig- Table II ) (23) . How is it possible that there was no therapeutic effect of DC expressing tumor Aghsp70 in this single immunization with small numbers of DC ( Fig. 1) ? Presumably, XBP1 constitutive expression in those DC might lead to some effects. Does XBP1 overexpression in DC regulate key molecules that can improve DC functions? Elevated XBP1 led to upregulation of Sec22b (a vesicle-trafficking protein and key DC Ag cross-presentation regulator) (32) and promoted cross-presentation of Ag (Fig. 5, Supplemental Fig. 1C, 1D ). By utilizing DC-specific XBP1-deficient mice, recent data show that XBP1 controls cross-presentation by CD8a + DC (16) . These results suggest the previously unknown function of XBP1 in crosspresentation by DC, but still one is left hanging as to what the essential features of XBP1 in DC will be. XBP1 constitutive expression in DC did not enhance Sec22b expression (Fig. 5) . Why is elevated XBP1 required to promote Sec22b expression? It is possible that a strong signal (i.e., sufficient amounts) of XBP1 in DC may be required to directly target Sec22b gene via binding to its promoter, leading to enhanced Sec22b expression. Possible binding sites of both mouse and human XBP1 on the promoter region of Sec22b gene were predicated (Supplemental Fig. 1E ). To define the direct effect of XBP1 on cross-presentation illustrates the sufficiency of XBP1 to augment DC-mediated cross-priming of T cells, it is worthwhile to investigate whether XBP1 regulates other cross-presentation-related gene expressions, enhances Sec22b to recruitment of endoplasmic reticulum components to DC phagosomes that are required for cross-presentation (32) , and improves the number of peptide/MHC complexes delivered to the surface of the DC.
DNA vaccines offer a potential for a large-scale vaccine platform, leading to a great practical promise for a high-impact in cancer immunotherapy but have limited ability to activate self/ tumor Ag-specific CD8 + T cells against the Ag-expressing native tumors. Melanoma self Ag TRP2-based DNA vaccines cannot elicit antitumor in particular therapeutic immunity in syngeneic B6 mice (25, 33) . Cross-presenting DC are preferred targets for cancer vaccines due to their "superior" ability to cross-present Ag (9). pDC are the major source for type I IFN, which is required in cross-presenting DC function (12) (13) (14) . DNA vaccines that enable harnessing cross-presenting DC and pDC may lead to potent antitumor CD8 + T cell immunity. Skin immunization with DC-targeting XBP1 DNA vaccines resulted in increased CD8a + DC frequency and absolute numbers in the skin dLN, transgene expression in DC from the skin dLN, and CD8 + T cell-dependent therapeutic immunity to B16, GL26, and 4T1.2-Neu (23). Skin harbors multiple DC subsets with different specialized functions and is the most accessible and ideal site for a vaccination (34) . Understanding the contribution of distinct skin DC subsets in the vaccine to the induction of effective tumor Ag-specific T cell immunity will provide important mechanistic insights and clinical implications for development of effective tumor vaccines. Braf CA Pten lox/lox by treatment with 4-HT and allowed to progress to a mean tumor size of ∼3 mm, at which point melanoma-bearing mice were randomized into cohorts of three to four mice with each cohort exhibiting a comparable mean tumor size. Animals were then left untreated or they were vaccinated using GG with XBP1/TRP2hsp70 cDNA on therapy days 0, 7, and 14. To deplete CD8 + T cells, anti-mouse CD8 mAb was injected i.p. 1 d before, on the day of, 1 and 3 d after the first vaccination, and then once a week thereafter. Tumor growth (A) and animal survival (i.e., time to euthanasia) (B) were then monitored. (C) Therapeutic vaccination was performed (A and B). On day 60, mice were sacrificed and CD8 + T cells were purified from splenocytes and tumor dLN. Purified CD8 + T cells were cocultured with syngeneic DC transfected by TRP2hsp70 DNA or pulsed by Braf V600E /Pten-driven melanoma lysates (NeuEDhsp70 DNA-transfected or 4T1.2-Neu lysate-pulsed DC as Ag-or tumor-specific controls) as described in Materials and Methods. IFN-g in the culture supernatants was then determined by ELISA. Data from two (CD8 depletion, CD8 + T cell responses) to four (tumor growth and animal survival) independent experiments are depicted. *p , 0.05, **p , 0.01, ***p , 0.001.
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Type I IFN promotes DC survival, maturation, and crosspresentation in CD103 + DC (12, 13, (35) (36) (37) and is naturally produced by rare populations of pDC in normal skin (38) . Elevated infiltration of the skin by pDC occurs after cutaneous trauma/injury (39) or in the case of cutaneous tumor progression (Supplemental Fig. 3) . Notably, our novel XBP1-based DNA vaccines increased IFN-a production by pDC in the skin/tumor dLN, which was required for optimal cross-priming of therapeutic CD8 + T cells by skin-derived Batf3 + DC (i.e., CD103 + DC) in our murine tumor models. IFN-a production by pDC and DNA vaccine efficacy was dramatically lower in the absence of XBP1 cDNA, supporting the need for its inclusion in optimally effective DNA-based vaccinations.
129S-or B6/129S-Batf3
2/2 (B6 backcrossed with 129S-Batf3 2/2 for five generations) mice are CD8a + and CD103 + DC deficient but have normal T cells and remaining DC subsets (8) (Supplemental Fig. 2B, 2C ). CD8a + DC and CD103 + DC are required for in vivo priming of spontaneous tumor-specific CD8 + T cells (12, 13) . XBP1 DC-targeting DNA vaccine-elicited antitumor immunity was abrogated in B6/129-Batf3 2/2 mice (Supplemental Fig. 2D ), suggesting that Batf3-dependent CD8a The number of CD8a + DC in skin dLN of B6-Batf3 2/2 mice is normal even though their cross-presentation ability is partially impaired (40) . XBP1 DC-targeting DNA vaccine-elicited antitumor immunity depended on Batf3-dependent CD103 + DC in skin dLN in both prevention (Fig. 3A) and therapeutic ( Fig. 3B-D) settings, indicating that skin migratory CD103 + DC are critical to the antitumor immunity induced by the XBP1 DC-targeting DNA vaccines.
Our data support the key role of Batf3-dependent CD103 + DC in effective cross-priming of protective antitumor immunity. However, cross-presenting DC in skin/tumor dLN may present secreted tumor Aghsp70 from Langerhans cells and/or dermal DC that take up the vaccine in the immunization sites and secrete Aghsp70 in the skin tumor dLN. Also, in skin immunization sites keratinocytes may take up the vaccine and secrete tumor Aghsp70, which may travel to the skin/tumor dLN where it is engulfed by CD103 + DC and cross-presented to CD8 + T cells. Alternatively, keratinocyte-secreted Aghsp70 may be in situ taken up by skin-resident DC (e.g., CD103
+ DC) and subsequently cross-present it to the skin-resident CD8 + T cells or migrate to the skin/tumor dLN for cross-priming of CD8 + T cells. It also remains unclear whether CD103 + DC deficiency-dampened cross-priming and antitumor responses are due to a defect in cross-presentation or to other causes (e.g., IL-12 production by CD103 + DC). Furthermore, although pDC are prime producers of IFN-a, and monocytes in vivo are a significant source for IFN-a (41), we have not yet formally established the in vivo cell source critical to the antitumor efficacy associated with effective Ag cross-presentation to therapeutic T cells. It will also clearly be of great prospective interest to determine whether ectopic XBP1 transactivates additional molecules associated with type I IFN (from pDC, monocytes) responsiveness and the effective MHC class I cross-presentation of Ag to CD8 + T cells by CD103 + DC. We have found comparative success of our XBP1/Aghsp70 DNA-based vaccine strategies across a range of tumor models; however, this approach, predicated on a single tumor Ag, is unlikley to provide optimal clinical benefit to cancer patients harboring tumors composed of a heterogeneous population of cells that vary in target Ag and MHC class I Ag processing machinery expression and tumor Ag loss during tumor progression. It will likely be important to integrate multiple tumor Ags into the DNA vaccine formulation, including private mutational Ags that have become increasingly recognized for their importance in determining clinical outcomes resulting from immunotherapy (42) . Vaccine-modulated DC that can acquire broad tumor-associated Ags, including tumor-derived debris, exosomes, and soluble Ag, and cross-present multiple tumor Ags, including the private mutational Ags, may have the greatest odds of promoting effective immunity. Efficient cross-presentation of Ag by XBP1 DC may explain the robust tumor (not just the vaccine Ag)-specific CD8 + T cell responses (Fig. 4C) . It is expected that vaccine-induced T cell responses will have to promote corollary rounds of endogenous tumor Ag cross-presentation to expand the protective antitumor CD8 + T cell repertoire (i.e., epitope spreading; see Ref. 43 ) to most effectively address the logistic issue of tumor heterogeneity. Additionally, the functional avidity of vaccine-induced T cells is anticipated to be critical to clinical outcome, with lowavidity T cells failing to recognize tumor cells in vivo and high-avidity T cells being preferentially tolerized within the immunosuppressive tumor microenvironment (44) . Whether XBP1/Aghsp70 gene-engineered DC condition moderate-to high-avidity Ag-specific CD8 + T cells that are refractory to tumor-induced anergy or apoptosis is currently being evaluated in our laboratory.
From a translational perspective, we were also able to demonstrate that (CD14 2 but not CD14 + ) DC emigrating from human skin explants vaccinated with human XBP1 and MAGEA3hsp70 cDNA (but not XBP1 or MAGEA3hsp70 cDNA alone) activated robust type 1 T cells in vitro. Any contribution of Langerhans cells will be determined by examining the capacity of these cells emigrating from these immunized human skin explants to activate human T cells. Among CD14
2 DC emigrating from skin are the recently discovered human CD141 + DC (HLA-DR + CD14
2 CD11c lo/2 CD141 hi ) subset (Supplemental Fig. 4B ), which appear to represent the human equivalents of mouse skin CD103 + DC (10, 11), the key cross-presenting DC for development of therapeutic immunity after immunization with our novel vaccine. These preliminary findings in human specimens provide enthusiasm for future translation of our novel genetic vaccine approach into pilot clinical trials for the treatment of patients with cancer.
In summary, our novel finding has substantial implications for cancer vaccine development even though the defined mechanisms by which XBP1 make DC "better" has not been fully established. The demonstrations of XBP1 function in both mouse and human DC and this novel vaccination potency in highly clinically relevant distinct tumor models including the stringent Braf V600E /Ptendriven melanoma will support its clinical translation.
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